Cross-Sectional and Longitudinal Associations of Comorbidities with Knee Symptoms and Radiographic Abnormalities of Osteoarthritis
ConclusionsHaving more comorbidities, especially diabetes and kidney diseases, is associated with symptomatic progression of knee OA. Moreover, non-OA musculoskeletal diseases may be associated with the presence and onset of ROA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 19, 2024 Category: Rheumatology Source Type: research
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
ConclusionRates of malignancy excluding NMSC were generally similar between UPA15, UPA30, ADA, and MTX and were consistent across RA, PsA, AS, and nr-axSpA. A dose-dependent increased rate of NMSC was observed with UPA in RA.Trial RegistrationClinicaTrials.gov identifier: NCT02706873, NCT02675426, NCT02629159, NCT02706951, NCT02706847, NCT03086343, NCT03104400, NCT03104374, NCT03178487, and NCT04169373. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 19, 2024 Category: Rheumatology Source Type: research
Real-World Burden of Immunosuppressant-Treated Lupus Nephritis: A German Claims Database Analysis
ConclusionsThis real-world analysis demonstrated the considerable burden of immunosuppressant-treated LN in Germany, with a high rate of discontinuations, frequent use of high-dose corticosteroids, and substantial HCRU/costs. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 19, 2024 Category: Rheumatology Source Type: research
Efficacy, Safety and the Lymphocyte Subset Changes of Low-Dose IL-2 in Patients with Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis
ConclusionLD-IL-2 treatment showed promise and was well tolerated in the management of ARDs, as it effectively promoted the proliferation and functional recovery of Tregs.Trial RegistrationRetrospectively registered (CRD42022318916, 21/04/2022). (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 19, 2024 Category: Rheumatology Source Type: research
Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 19, 2024 Category: Rheumatology Source Type: research
Correction: Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 19, 2024 Category: Rheumatology Source Type: research
Correction: Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 19, 2024 Category: Rheumatology Source Type: research
Correction: Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA)
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 19, 2024 Category: Rheumatology Source Type: research
Impact of the COVID-19 Pandemic on People Living with Rheumatoid Arthritis: Experiences and Preferences in Accessing Healthcare Across Five Countries
ConclusionsThis survey suggests that the COVID-19 pandemic did negatively impact some aspects of disease management for people living with RA but had positive impacts on the utilization of virtual care. Although participants generally preferred in-person appointments, these results position virtual care as an appropriate means for routine follow-ups. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 13, 2024 Category: Rheumatology Source Type: research
Characteristics of COVID-19 and Impact of Disease Activity in Patients with Adult-Onset Still ’s Disease
ConclusionPatients with AOSD receiving medium or high-dose glucocorticoid therapy or JAK inhibitors had worse COVID-19 outcomes. Further work is needed to explore risk factors affecting COVID-19 outcomes and the impact of COVID-19 on disease activity in AOSD. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 6, 2024 Category: Rheumatology Source Type: research
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
ConclusionsThe results of this integrated long-term analysis of laboratory parameters continue to support an acceptable safety profile of UPA 15 mg QD for moderate-to-severe RA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 5, 2024 Category: Rheumatology Source Type: research
Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases and Serum Antibody Changes Post-Omicron Variant Infection
ConclusionsSARS-CoV-2 inactivated vaccines have similar protective effects in HCs and patients with RMDs, with an appreciable safety profile. Fully vaccinated patients with RMDs infected with the Omicron variant were able to produce effective neutralizing antibody concentrations. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 4, 2024 Category: Rheumatology Source Type: research
The Role of Early Treatment in the Management of Axial Spondyloarthritis: Challenges and Opportunities
AbstractAxial spondyloarthritis (axSpA) is a chronic, inflammatory rheumatic disease that primarily affects the axial skeleton, often inflicting severe pain, diminished mobility, and a compromised quality of life. The advent of Assessment of SpondyloArthritis international Society (ASAS) classification criteria for spondyloarthritis (SpA) have enabled the classification of patients with axSpA in the non-radiographic stage but poorly perform if mistakenly used for diagnostic purposes. Despite notable progress in early diagnosis facilitated by referral strategies and extensive magnetic resonance imaging (MRI) utilization, di...
Source: Rheumatology and Therapy - December 18, 2023 Category: Rheumatology Source Type: research
Adalimumab Effectively Decreases Inflammation Downstream of TNF α Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis
ConclusionsThis data suggests that, after only 24 h, adalimumab is effective at decreasing inflammation that occurs downstream of initial TNFα signaling in extended-to-be fibroblast-like synoviocytes. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 9, 2023 Category: Rheumatology Source Type: research
Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis
ConclusionsGreater proportions of MTX-IR current/former smokers responded to FIL200 + MTX vs. adalimumab + MTX. In non-smoking MTX-IR, bDMARD-IR, and MTX-naïve patients with RA, FIL200 + MTX demonstrated increased response vs. controls. Current/former smokers were likelier to discontinue adalimumab vs. non-smokers in real-world clinical settings.Trial RegistrationNCT02889796, NCT02873936, NCT02886728. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 6, 2023 Category: Rheumatology Source Type: research
